NCT03586661View on ClinicalTrials.gov

Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

April 29, 2019

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Deleterious BRCA1 Gene MutationDeleterious BRCA2 Gene MutationEndometrial AdenocarcinomaHigh Grade Ovarian Serous AdenocarcinomaPlatinum-Resistant Ovarian CarcinomaPrimary Peritoneal High Grade Serous AdenocarcinomaProgressive DiseaseRecurrent Endometrial CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma
Interventions
DRUG

Copanlisib

Given IV

DRUG

Niraparib

Given PO

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER